SanBio Company Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNBIF research report →
Price Chart
About the company
SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States and Japan for the treatment of traumatic brain injury (TBI). The company's research pipeline also explores the potential of SB623 for a variety of other conditions, including ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others.
- CEO
- Keita Mori
- IPO
- 2015
- Employees
- 33
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on SNBIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.28B
- P/E
- -18.21
- Fwd P/E
- 0.86
- PEG
- 14.83
- P/S
- 0.00
- P/B
- 5.79
- EV/EBITDA
- -15.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.79%
- ROIC
- -28.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-8,052,893+0.0%
- Op Income
- $-3,794,349,976
- Net Income
- $-3,842,146,194-33.3%
- EPS
- $-52.63-25.8%
- OCF Growth
- -5.6%
- FCF Growth
- -6.4%
- 52W High
- $16.45
- 52W Low
- $3.85
- 50D MA
- $16.45
- 200D MA
- $16.45
- Beta
- 0.28
- RSI (14)
- 52
- Avg Volume
- 667
No earnings-call transcripts are available for SNBIF yet.
- Free Float
- 72.8%
- Shares Outstanding
- 78.04M
- Float Shares
- 56.81M
Our SNBIF coverage
Recent articles, reports, and earnings notes.
No research on SNBIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNBIF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.